登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>CCL20 >CC0-H51H3

Human CCL20 Protein, His Tag (HPLC verified)

分子别名(Synonym)

C-C motif chemokine 20,Beta-chemokine exodus-1,CC chemokine LARC,Liver and activation-regulated chemokine,Macrophage inflammatory protein 3 alpha,MIP-3-alpha,Small-inducible cytokine A20,CCL20

表达区间及表达系统(Source)

Human CCL20 Protein, His Tag (CC0-H51H3) is expressed from E. coli cells. It contains AA Ala 27 - Met 96 (Accession # P78556-1).

Predicted N-terminus: Met

Request for sequence

蛋白结构(Molecular Characterization)

CCL20 Structure

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 10 kDa. The protein migrates as 11-12 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

>90% as determined by SEC-HPLC.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 0.085% TFA 30% ACN with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

CCL20 SDS-PAGE

Human CCL20 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-HPLC

CCL20 SEC-HPLC

The purity of Human CCL20 Protein, His Tag (Cat. No. CC0-H51H3) was greater than 90% as determined by SEC-HPLC.

 
评论(1)
  1. 176XXXXXXX7
  2. 6人赞
  3. ACRO的IL-2系列的蛋白用了好几种tagd~每种标签都很奈斯,结合活性结果重现性很好,官方的PROTOCOL条件很精准~基本重现没有太多误差。好评
  4. 2023-2-22
  1. 159XXXXXXX4
  2. 3人赞
  3. 今天使用了商品,实验效果不错哦,结果和预期的比较符合,后续会针对结果继续分析讨论,看看是否再次进行重复实验。
  4. >
  5. 2023-3-13
  1. 153XXXXXXX3
  2. 2人赞
  3. 我们用此蛋白用于小鼠体内动物实验,探讨重组IL2在小鼠体内实验的最大耐受剂量以及有效性,作为一个对标分子,数据持续更新中,并且结果满足期待,Acro蛋白质量很高,值得信赖,推荐。
  4. 2023-7-6
 
ACRO质量管理体系
 
 

背景(Background)

This antimicrobial gene belongs to the subfamily of small cytokine CC genes. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The protein encoded by this gene displays chemotactic activity for lymphocytes and can repress proliferation of myeloid progenitors. Two transcript variants encoding different isoforms have been found for this gene.

 

前沿进展

Enhanced Antitumor Immunity Through T Cell Activation with Optimized Tandem Double-OX40L mRNAs
Deng, Tian, Wang et al
Int J Nanomedicine (2025) 20, 3607-3621
Abstract: The tumor immune microenvironment (TIME) is often dysfunctional and complex, contributing to tumor metastasis and drug resistance. This study investigates the use of mRNA-based cancer agents as promising tools to combat and reverse refractory TIME conditions.We optimized and engineered an mRNA cancer agent encoding double tandemly repeated sequences of the T cell costimulator Oxford 40 ligand (diOX40L). The diOX40L mRNAs were encapsulated into lipid nanoparticles (LNPs) for effective delivery. The research explored its safety and antitumor effects through a series of in vivo and in vivo experiments.Our results demonstrate that diOX40L mRNAs efficiently express increased levels of OX40L proteins. The optimized diOX40L mRNA cancer agent generated potent immune costimulatory signals within the TIME, leading to decreased tumor growth and improved survival compared to the original sequence agent. OX40L expression in subcutaneous tumors promoted CD4+ and CD8+ T cell activation, resulting in heightened IFN-γ and IL-2 secretion and robust immune responses. Combination therapy involving PD-1 antibodies and diOX40L substantially enhanced antitumor efficacy, with increased infiltration of activated CD4+ and CD8+ T cells.In conclusion, our findings highlight the therapeutic potential of the optimized diOX40L mRNA cancer agent in cancer treatment and its potential as an innovative alternative to protein-based therapies. The study underscores the significance of mRNA-based agents in modulating the immune microenvironment and enhancing antitumor responses.© 2025 Deng et al.
OX40 ligand promotes follicular helper T cell differentiation and development in mice with immune thrombocytopenia
Yang, Hai, Chen et al
J Zhejiang Univ Sci B (2025) 26 (3), 240-253
Abstract: Immune thrombocytopenia (ITP) is a hemorrhagic autoimmune disease characterized by antibody-mediated platelet injury. ITP has complicated immunopathological mechanisms that need further elucidation. It is well known that the costimulatory molecules OX40 ligand (OX40L) and OX40 play essential roles in the immunological mechanisms of autoimmune diseases. Previously, we discovered that the expression of OX40L and OX40 is significantly increased in the peripheral blood mononuclear cells (PBMCs) of ITP patients. In our present study, OX40L-induced follicular helper T (Tfh) cells exhibited an activated phenotype with elevated expression of inducible T-cell costimulator (ICOS), programmed cell death protein-1 (PD-1), and cluster of differentiation 40 ligand (CD40L) in vitro. Moreover, aberrant OX40L‒OX40 expression might promote the Tfh1-to-Tfh2 shift in vivo, inducing the generation of autoantibodies by enhancing the helper function of Tfh cells for B lymphocytes in a mouse model, which might accelerate the progression of ITP. Additionally, signal transduction through the OX40L‒OX40 axis might be related to the activation of tumor necrosis factor receptor-associated factor (TRAF)‒nuclear factor-κB (NF-κB) and Janus kinase (JAK)‒signal transducer and activator of transcription (STAT) signaling pathways. Overall, OX40L‒OX40 signaling is proposed as a potential novel therapeutic target for ITP.
[Celiac disease: Novel pharmacological therapies]
Schuppan, Neufang, Wanger
Dtsch Med Wochenschr (2025) 150 (6), 273-279
Abstract: Coeliac disease is the most common chronic inflammatory disease of the small intestine, with a prevalence of around 1% almost worldwide. It is caused by the consumption of cereals containing gluten (wheat, spelt, rye, barley). The initial diagnosis is made in equal proportions in children and adults. Classic symptoms are abdominal pain, diarrhea, malabsorption with anemia or osteoporosis, weight loss, and in children failure to thrive. Non-specific symptoms such as poor performance, headaches and joint pain are also common. Often undetected and untreated, coeliac disease can lead to serious complications, and up to 30% of adult coeliac patients suffer from associated autoimmune diseases, including thyroid and rheumatoid diseases or type 1 diabetes. The pathogenesis of coeliac disease is well studied. Incompletely digested gluten peptides reach the immune system of the intestinal mucosa and activate glute-reactive T cells, which lead to inflammation and atrophy of the absorptive villi. The prerequisite for the development of coeliac disease is the carrier status for HLA-DQ2 or DQ8, as well as the enzyme and coeliac disease autoantigen transglutaminase-2 expressed in the intestine, which modifies the gluten peptides by deamidation and thus increases their binding to HLA-DQ2/DQ8 and subsequent T-cell activation. Despite the gluten-free diet, 30-50% of diagnosed patients continue to suffer from symptoms with signs of inflammation, partly due to unavoidable minimal gluten contamination in everyday life. Supportive pharmacological therapy is therefore urgently needed. Promising therapeutic approaches are currently in clinical phase 2 development, including an inhibitor of intestinal TG2, blocking antibodies against interleukin-15 or Ox40 ligand, the improvement of the intestinal barrier using a sirtuin-6 agonist, as well as nanoparticular therapies that can induce tolerance to gluten by addressing the spleen or liver.Thieme. All rights reserved.
Showing 1-4 of 1006 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
CCL20靶点信息
英文全称:C-C motif chemokine 20
中文全称:CC类趋化因子20
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:0详情
最高研发阶段:临床前
查看更多信息
前沿进展
点击查看详细
相关产品
View All CCL20

消息提示

请输入您的联系方式,再点击提交!

确定